Abstract: The present disclosure provides for systems, methods, and devices for facilitating conception. According to the present disclosure, a conception facilitating device may comprise at least one frame and at least one base. In some embodiments, the at least one frame may be configured to at least partially surround the at least one base. In some aspects, the conception facilitating device may be configured to be insertable into a vaginal canal. The conception facilitating device may be comfortably inserted into a vaginal canal for a period of time, which may increase the possibility of conception.

Abstract: Systems, apparatus, and methods are described for delivering a therapeutic substance to a target area within or proximate to a nasal cavity of a subject, including a reservoir configured to contain the therapeutic substance and a delivery interface by which the therapeutic substance is delivered to the target area. In some embodiments, systems, apparatus, and methods described herein can deliver a therapeutic substance using iontophoresis and/or electroosmosis.

Abstract: An implantable electrode arrangement for a cochlear implant system includes an elongated electrode array for insertion into a patient cochlea. A fluid delivery channel is located within the electrode array parallel to a central longitudinal axis with at least one fluid delivery port for delivering lubricant fluid from the fluid delivery channel to the outer surface of the electrode array. The fluid delivery port and the lubricant fluid are configured to produce a lubrication region close to the outer surface of the electrode array proximal to the fluid delivery port during insertion of the electrode array into the patient cochlea so as to reduce insertion resistance at an adjacent section of lateral wall of the patient cochlea.

Abstract: A closure device system for sealing a percutaneous puncture in a vessel wall can include a toggle configured to engage an interior surface of the vessel wall, a plug configured to engage an exterior surface of the vessel wall, and a suture that extends through the plug and through the toggle along at least a first direction so as to couple the toggle to the plug. The system can further include a tube that extends through the plug and through the toggle along the first direction such that a distal end of the tube is disposed distally to the toggle. The tube can define a guidewire lumen that extends therethrough along the first direction. And the guidewire lumen can be configured to receive a guidewire that protrudes from the vessel wall such that the plug, toggle, and tube are slidable along the guidewire toward the vessel wall.

Abstract: The present technology relates generally to a method and device for closing percutaneous punctures, and more particularly to a multi-lumen tamper for such a device. A closure device for sealing a percutaneous puncture in a wall of a body passageway is disclosed, the closure device including a plug configured to engage a surface of the puncture; a toggle configured to engage an internal surface of the body passageway; an elongate filament configured to associate the plug with the toggle; a locking member configured to engage the plug; and a tamper comprising at least two lumens, wherein a first lumen of the at least two lumens is configured to deliver a pharmaceutical agent to the plug.

Abstract: Embodiments of the present disclosure are directed to medical devices, methods, and systems for delivering a medical device to a target site. In one embodiment, a medical device includes a proximal lobe and a distal lobe, at least one of the proximal lobe or the distal lobe configured to receive a delivery device therethrough. The medical device also includes a central engagement member disposed between the proximal lobe and the distal lobe, the central engagement member configured to be engaged by a delivery device for facilitating deployment of the proximal and distal lobes at the target site.

Abstract: The present disclosure describes a tampon article, a composite fibrous web, and a method of making same. Such an article includes an outer carrier component including an inner surface that defines an internal void. Including an absorbent component elongate along an axis and is disposed in the internal void. The absorbent component includes an outer surface that extends about the axis and faces the inner surface. The absorbent component further includes a composite fibrous web of staple cellulosic fibers and a meltspun web of filaments entangled with the web of staple cellulosic fibers. The composite fibrous web can be in a compressed configuration in the internal void such that at least portion of the outer surface of the absorbent component is defined by the meltspun web of filaments. The tampon can include a withdrawal cord coupled to the absorbent component.

Abstract: A left atrial appendage occluder includes a sealing plate, a fixing plate, and a connection member connecting the sealing plate and the fixing plate. The connection member is a silk woven structure. A radial deformability of the sealing plate is greater than a radial deformability of the fixing plate, and/or an axial deformability of the sealing plate is greater than an axial deformability of the fixing plate. In the left atrial appendage occluder, the fixing plate and the sealing plate are connected via the connection member of the silk woven structure, such that a distance between the fixing plate and the sealing plate and an angle formed thereby are both adjustable to adapt to a left atrial appendage having a large bending angle or requiring the fixing plate to remain at an increased distance to the sealing plate, thereby reducing the risk of failed occlusion.

Abstract: A device, method, and use of a device for temporary management of a wound, such as a wound in a heart. The device has a shaft, a blood flow blocking membrane at the first end of the shaft for blocking blood flow through the wound, and an abutment member that is mounted to the shaft and is axially movable along the shaft towards and away from the blood flow blocking membrane for abutting the wound and holding the blood flow blocking membrane adjacent the wound. The blood flow blocking membrane is resiliently flexible and movable between at least a first collapsed state for inserting the blood flow blocking membrane through the wound, and a deployed state for blocking blood flow through the wound.

Abstract: A closure device system for sealing a percutaneous puncture in a vessel wall can comprise a toggle configured to engage an interior surface of the vessel wall, a plug configured to engage an exterior surface of the vessel wall, and a suture that extends through the plug and through the toggle along at least a first direction so as to couple the toggle to the plug. The system can further comprise a tube that extends through the plug and through the toggle along the first direction such that a distal end of the tube is disposed distally to the toggle. The tube can define a guidewire lumen that extends therethrough along the first direction. And the guidewire lumen can be configured to receive a guidewire that protrudes from the vessel wall such that the plug, toggle, and tube are slidable along the guidewire toward the vessel wall.

Abstract: Devices, systems and methods for repairing a valve in a patient's heart includes a two or more fixations devices, each fixation device being attachable to the free end of a target tissue, such as a valve leaflet, the fixation devices being coupled together by a coupling device capable of repositioning and coupling the fixation devices in order to re-position the free ends of the valve leaflets.

Abstract: A device for sealing a puncture opening may include a base frame having a delivery configuration wherein the base frame is retracted to have a relatively smaller overall profile, and a deployed configuration wherein the base frame is extended to have a relatively larger overall profile. The base frame is sized to engage an interior surface of the blood vessel wall in the deployed configuration. A sealing section is coupled to the base frame, the sealing section having an initial configuration wherein the sealing section permits fluid flow, and a barrier configuration wherein the sealing section prevents fluid flow. The sealing section in the barrier configuration is sized to block fluid flow through the puncture opening when the base frame is in the deployed configuration.

Abstract: A system for sealing a large penetration in the wall of a femoral artery comprises an occlusion catheter and an applicator. An access catheter may further be provided in order to facilitate introduction of the occlusion catheter. The occlusion catheter is introduced through a contralateral penetration, advanced over the aortic bifurcation, and an occlusion element on the occlusion catheter is positioned at the large diameter penetration. The occlusion element is then inflated to temporarily seal the large penetration while blood perfusion past the occlusion element is provided by the catheter. A sealing material, such as a tissue adhesive or other hemostatic agent is then introduced into a tissue tract above the large diameter penetration in order to seal the penetration. The occlusion element may be left in place while the sealing material has time to set, cure or otherwise form a permanent seal of the large penetration. The occlusion catheter and all access sheaths may then be removed from the patient.

Abstract: Implantable medical devices for connecting tissue layers, such as for connecting a gallbladder and a portion of a gastrointestinal tract to create an anastomosis, include a tubular structure having a plurality of apposition portions, a central region, and a covering material. The devices are endoscopically deployable and may include flange members having hinge members or variable properties such as length, angle, shape, material stiffness, and wire diameter.

Abstract: A method of treating early papillomavirus infection of an orifice of a human or animal body including any canal associated with an orifice, comprising applying a viral inactivation agent to the orifice and/or canal in an amount effective to inactivate a portion of the virus infecting the orifice or canal. Apparatus is also disclosed.

Abstract: A seal assembly that seals opening in the wall of a blood vessel has a first sealing element for placing inside the lumen of the blood vessel and to engage the interior wall surface, a shaft integrally formed with the first sealing element and fixed in a predetermined configuration relative to the first sealing element, an outer floating element slidingly movable along the shaft; and a second sealing element, the second sealing element slidingly movable relative to the first sealing element along the shaft to engage the outer floating element and position the outer floating element against the exterior surface and the first sealing element against the interior surface of the blood vessel to seal the opening in the blood vessel.

Abstract: Provided are approaches to establish a failsafe barrier to internal bleeding from percutaneous wounds to protect a patient from failed wound closure devices or related complications due to a variety of contributing factors such as state of systemic anticoagulation, errors in surgical procedure, variability in patient anatomy, and the like. Systems include a clotting agent to encase, and thus isolate, substantially the entire wound access area from the rest of the patient and an instrument, such as an intravascular introducer sheath, inserted through a wound at an access site on a vessel, for delivering the clotting agent to the entire enveloping tissue region around the accessed area as a mold cavity to be filled with the clotting agent. With benefits of patient safety, user simplicity, and low healthcare cost driving the effort, autologous whole blood is the preferred injected agent.

Abstract: A pneumatic compression device for non-invasive external intermittent pneumatic compression system used as prophylaxis for reducing the incidence of Deep Vein Thrombosis (DVT). The system consists of a pneumatic compression pump, valves for control of air flow, a pressure sensor, and a controlling circuitry. The controlling circuitry receives input from the pressure sensor and switch ON/OFF one or more control valves based on the pressure sensor input to dynamically controlling the pressure of the regulated compressed air flow.

Abstract: The present invention provides an improved vascular occlusion device having improved flexibility and retention of the type fabricated from braided tubular metal fabric having an expanded preset configuration and an elongated collapsed reduced diameter configuration for delivery through a catheter to a treatment site and shaped to create an occlusion of an abnormal opening in a body organ or vessel, the woven metal fabric having a memory property whereby the medical device tends to return to said expanded preset configuration when unconstrained. The device further including at least one disk portion adjacent a body cylindrical portion formed from the fabric and having a transition diameter between the disk and cylindrical portion, significantly smaller than the diameter of the disk and the diameter of the cylindrical portion.

Abstract: The present disclosure describes an occlusion device and methods of delivering the occlusion device. The occlusion device can include an expandable structure configured to move between an unexpanded configuration and an expanded configuration. The expandable structure can be configured to have an expansion ratio of at least about 5:1. Further, the occlusion device can be configured to prevent substantially all fluid from flowing past the occlusion device when the occlusion device is in the expanded configuration in the vessel.

Abstract: Devices and methods for treating vascular defects, such as, for example, balloon-type aneurysms, are described herein. In one embodiment, an apparatus includes an insertion portion and an expandable implant. The expandable implant is configured to be deployed in an aneurysm and is coupled to the insertion portion. The expandable implant has a first portion and a second portion coupled to the first portion. The expandable implant is movable between a first configuration in which the first portion and the second portion are substantially linearly aligned and a second configuration in which the second portion at least partially overlaps the first portion.

Abstract: A tissue anchor includes an anchor member formed from a generally flexible material. An activation member, which may be a tensioning member, causes proximal and distal end portions of the anchor member to move toward each other into a shortened configuration suitable for anchoring against the tissue. The tissue anchor can optionally be deployed and activated using a catheter device.

Abstract: The present technology relates generally to a method and device for closing percutaneous punctures, and more particularly to a multi-lumen tamper for such a device. A closure device for sealing a percutaneous puncture in a wall of a body passageway is disclosed, the closure device including a plug configured to engage a surface of the puncture; a toggle configured to engage an internal surface of the body passageway; an elongate filament configured to associate the plug with the toggle; a locking member configured to engage the plug; and a tamper comprising at least two lumens, wherein a first lumen of the at least two lumens is configured to deliver a pharmaceutical agent to the plug.

Abstract: An occlusive device includes a frame element having a distal end and a proximal end, and a delivery configuration and a deployed configuration. The occlusive device also includes an occlusive face having a peripheral edge, where the occlusive face positioned toward the proximal end of the frame element. The occlusive device also includes at least one anchor positioned at the peripheral edge of the occlusive face, where the at least one anchor extends at an acute angle to the peripheral edge of the occlusive face.

Abstract: A prosthetic mitral valve comprising an expandable anchor comprising a first anchor, a central portion and a second anchor; wherein the first anchor comprises a first outer frame and a second outer frame, the first outer frame comprising a plurality of first arcs joined together, and the second outer frame comprising a plurality of second arcs joined together, wherein the plurality of first arcs are out of phase relative to the plurality of second arcs when the first anchor is viewed in an end view from the first anchor to the second anchor; and a plurality of replacement leaflets secured to the expandable anchor.

Abstract: An apparatus comprises an absorbent body, a non-permeable feature, and a port feature. The absorbent body comprises a wicking feature. The non-permeable feature is coupled with the absorbent body. The non-permeable feature and at least a portion of the absorbent body are configured to fit in an opening in a paranasal sinus wall. The port feature extends through the absorbent body. The port feature defines a lumen. The wicking feature extends outwardly relative to the port lumen. During installation of the apparatus, the non-permeable feature is positioned in an opening in the paranasal sinus wall. The absorbent body is oriented such that the wicking feature is in contact with mucosal tissue in a sinus cavity defined by the paranasal sinus wall. A proximal portion of the absorbent body is positioned outside the paranasal sinus wall.

Abstract: The invention relates to the use of one or more oligomers of lactic acid or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefits from an acidic environment, especially a gynaecological infection including a bacterial infection such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis (Candida albicans), cryptococcosis, actinomycosis, or a viral infection, such as Human Immunodefiency Virus (HIV), Herpes Simplex Virus (HSV), Human Papilloma Virus (HPV).

Abstract: A method of preparing a substantially planar microdevice comprising a plurality of reservoirs is provided. In general, the method comprises forming a plurality of microdevices comprising a plurality of reservoirs from a planar layer of a biocompatible polymer. The method also comprises depositing one or more bioactive agents into the reservoirs. The microdevice is configured to attach to a target tissue and release the bioactive agent in close proximity to the tissue.

Abstract: Devices and methods for transmucosal drug delivery are provided. A device includes a housing configured for intralumenal deployment into a human or animal subject; a drug-dispensing portion which contains at least one drug; and a plurality of microneedles extending, or being extendable from, the housing, the plurality of microneedles being configured to disrupt at least one region of a mucosal barrier adjacent the housing at a selected time after being intralumenally deployed in the human or animal subject. The device is operable to dispense the drug from the housing to a region of the mucosal barrier disrupted by the plurality of microneedles.

Abstract: Intralumenal devices and methods are provided for transmucosal drug delivery. The device may comprise a housing configured for intralumenal deployment into a human or animal subject; a drug-dispensing portion which contains at least one drug; and an electrically-actuatable portion configured to disrupt at least one region of a mucosal barrier adjacent to the housing at a selected time while intralumenally deployed in the human or animal subject. The device may be operable to dispense the drug from the housing to a region of the mucosal barrier disrupted by the electrically-actuatable portion.

Abstract: Drug delivery devices, medicaments, and methods are provided for the intraperitoneal treatment of ovarian cancer. An implantable device for drug delivery includes an elongated, flexible device having a housing defining a reservoir that contains a drug in solid or semi-solid form, and configured to be wholly deployed within the peritoneal cavity of a patient and continuously release a therapeutically effective amount of the drug over a period of at least 24 hours. A medicament includes cisplatin for administration into the peritoneal cavity of a patient continuously over a treatment period of at least 24 hours. A method of drug delivery includes implanting within the peritoneal cavity of a patient an elongated, flexible device having a reservoir containing a drug, solubilizing the drug at least in part with peritoneal fluid, and releasing an effective amount of the solubilized drug from the reservoir continuously for a period of at least 24 hours.

Abstract: Described herein is an apparatus to insert an implantable therapeutic device into a patient. The apparatus includes a proximal handle (210) and a distal placement portion (220) coupled to the proximal handle and configured to hold the implantable therapeutic device. The distal placement portion includes a first side (222) having a first engagement structure (251) at a distal end of the first side, the first engagement structure configured to surround at least a first portion of a proximal end region of the implantable therapeutic device. The distal placement portion includes a second, opposite side (224) having a second engagement structure (253) at a distal end of the second side, the second engagement structure configured to surround at least a second, opposite portion of the proximal end region of the implantable therapeutic device.

Abstract: A biomaterial mass is inserted through a punctum into a canaliculus in the lacrimal outflow system with a syringe. The mass has an outer cross section that is less than the inner cross section of the canaliculus. The mass absorbs liquid to swell to form a lacrimal filler or sealing mechanism. The lacrimal filler has an external cross section that conforms to the internal cross section of the canaliculus and a soft outer surface relative to the surrounding tissues to prevent erosion of the canaliculus lining. The lacrimal filler forms an occlusion that prevents the outflow of liquid through the lacrimal outflow system to retain tears within the eye to maintain eye lubrication and wetness. The mass and syringe are provided in kit with a rubber stopper and, optionally, a punctal dilator, an injecting catheter, and an enzyme for dissolving or degrading the lacrimal filler at a later time.

Abstract: Devices and methods are provided for transmucosal drug delivery. The transmucosal drug delivery device may include a housing configured for intralumenal deployment, such as intravaginally, into a human or animal subject; a drug-dispensing portion which contains at least one drug, the drug-dispensing portion being configured to dispense the drug from the housing by positive displacement; and a permeability enhancer-dispensing portion configured to release or generate a permeability enhancing substance to disrupt at least one region of a mucosal barrier adjacent to the housing at a selected time while intralumenally deployed in the human or animal subject. The device may be operable to dispense the drug from the housing to a region of the mucosal barrier disrupted by the permeability enhancing substance.

Abstract: Provided is a medical system including a first capsule type medical device, and a second capsule type medical device. The first and second capsule type medical devices operate in cooperation with each other in a body.

Abstract: An orthopaedic implant system includes an external fixation device implantable at a selected location within a corporeal body and configured for delivering at least one therapeutic agent to the corporeal body. The external fixation device includes an implantable pin, a sheath coupled with the pin, a reservoir coupled with the sheath and a plurality of channels. The pin defines the plurality of channels. The reservoir is configured for receiving the at least one therapeutic agent. The plurality of channels are configured for conveying the at least one therapeutic agent from the reservoir to a treatment site relative to the corporeal body.

Abstract: A surgical technique and device wherein an indwelling tube is placed in the eye of a patient having glaucoma. The tube diverts aqueous humor from the anterior chamber to the suprachoroidal space from which it is removed by blood flowing in the choroidal and uveal tissues. This decreases the intraocular pressure.

Abstract: Implant devices for intravesical administration and local drug delivery. The device has a body which includes a hollow tube formed of a biocompatible material; at least one reservoir in the tube which contains a drug; and one or more apertures through which the drug can be released. The device is configured for minimally invasive insertion into a body cavity, such as the bladder. The hollow tube may be elastomeric to permit the device to be elastically deformed from its initial shape into an elongated shape for passage through a catheter, where following such passage the device can return to or toward its initial shape to facilitate retention of the device in the body cavity. The body may have a narrow, elongated shape effective to permit insertion of the drug delivery device through a catheter without necessarily deforming the body, yet include flexible projections which effect retention within the body cavity.

Abstract: The present invention provides a novel drug delivery system for the controlled release of therapeutically active substances at a predetermined, essentially constant release rate over a prolonged period of time. The delivery system comprises at least one core comprising said therapeutically active substance(s), at least one membrane encasing the core and an intermediary layer of a substantially inert material, wherein the intermediary layer is applied between the core and the membrane or between two membrane layers.

Abstract: The present invention relates to a device for intermittently obstructing a bodily opening, such as a gastric opening, and includes a proximal member connected to a distal member by a tether. The proximal member includes an apron member surrounding a first occluding member, which is formable from an elongated and narrower configuration to a contracted or expanded but wider configuration. When employed in the stomach, the device of the present invention is arranged transluminally, with the distal member disposed in the duodenum and the proximal member disposed against the pyloric valve, intermittently occluding the pyloric valve and preventing or delaying the flow of gastric contents through the pyloric valve. In certain embodiments, a reservoir may be included for releasing a substance of interest, for example for releasing insulin from a reservoir disposed in the distal member. Sensors, actuators, and data transmission devices may also be included.

Abstract: A blood coagulating device can include an absorbent body; and a hemostatic lysine composition associated with the body. The body can have a cylindrical or conical member having a first end having the hemostatic composition, the first end being configured for insertion into a nasal passageway. A method for coagulating blood can include providing a powdered hemostatic lysine composition; and applying the powdered hemostatic lysine composition to blood so as to cause the blood to coagulate and form a clot. The coagulation can occur in a nasal passageway away from a blood vessel. The method can include providing at least one absorbent member having the powdered hemostatic lysine composition; and applying the at least one absorbent member to the blood so that the powdered hemostatic lysine composition causes the blood to coagulate and clot.

Abstract: An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.

Abstract: The present invention relates to the field of drug delivery systems. More particularly, the invention relates to osmotically active intravaginal delivery systems for the controlled release of therapeutically active substances to the vaginal cavity.

Abstract: An applicator for delivering a single dose of medicine into an inner canal of a person using a finger is disclosed. In one embodiment, the applicator includes a body having an open end and a closed end. A substantially solid compounded medicine is attached to the outer surface of the closed end of the body. The substantially solid compounded medicine melts to a liquid when disposed within the inner canal of the ear. A projection extends outwardly from the closed end of the body, with the compounded medicine surrounding the projection.

Abstract: The invention relates to a pharmaceutical formulation for sustained delivery of a therapeutic agent, preferably a protein, polypeptide, an antibody or an antibody fragment, comprising one or more gel forming peptides wherein the formulation exhibits sustained delivery for at least two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, ten weeks, eleven weeks, twelve weeks or more. In one embodiment, the invention relates to a formulation comprising self-assembling peptides that undergo sol-gel transition in the presence of an electrolyte solution such as biological fluids and salts. The formulation can provide sustained release of antibody and antibody fragments, in particular, IgG. Antibody diffusivities can be decreased with increasing hydrogel nanofiber density, providing a means to control the release kinetics.

Abstract: The present invention consists of an implantable structural element for in vivo delivery of bioactive active agents to a situs in a body. The implantable structural element may be configured as an implantable prosthesis, such as an endoluminal stent, cardiac valve, osteal implant or the like, which serves a dual function of being prosthetic and a carrier for a bioactive agent. Alternatively, the implantable structural element may simply be an implantable article that serves the single function of acting as a time-release carrier for the bioactive agent.

Abstract: An occlusion device for closing an anatomical defect in tissue comprising a conduit connecting an opening on a first tissue and an opening on a second tissue is provided. The occlusion device comprises a scaffold comprising a) a proximal support structure comprising at least two arms; b) a distal support structure comprising at least two arms, wherein the arms are adapted to provide anchorage for the device in the tissue; and c) a waist portion adapted for extending through the opening on the first tissue and connecting the proximal support structure with the distal support structure, wherein the scaffold consists essentially of a biodegradable polymer, wherein the proximal support structure and the distal support structure comprise or consist of polycaprolactone (PCL), poly-(D,L-lactide-co-caprolactone) (PLC), or a mixture thereof. A method of closing an anatomical defect using the occlusion device is also provided.

Abstract: The present invention provides for a drug delivery device. The device can comprise at least one core with a first active pharmaceutical ingredient (API), coated with a first layer that is permeable or semi-permeable to the API, coated with a second layer that is impermeable to the API, and having a delivery window to allow passage of the API through the device and into body fluids or tissues. The device can also have a wicking material to modify the rate of transport of the API into the body fluid or tissues.

Abstract: Systems, devices, and methods are described for providing, among other things, devices operable to acquire intestinal microbial flora samples, to map intestinal microbial flora, to identify microbes present in an individual's digestive tract, to delivery intestinal microbial flora compositions, to register a microbial flora collection events, to register microbial flora-seeding events, or the like.

Abstract: Lung volume reduction by isolating a target lung portion from the rest of the lung with a mass of extracellular matrix (“ECM”) material. The procedure can be performed by locating a tube within the lumen of an airway to be obstructed and depositing an amount of flowable or other ECM in the open space until the lumen is occluded. Optionally, the procedure may be performed by delivering a plug substantially comprised of ECM material into the lumen of an airway to be obstructed. Further optionally, the ECM plug may include a one-way valve to allow air and mucous to escape from the isolated lung portion.